These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34303789)

  • 41. Proteasomal degradation of sphingosine kinase 1 and inhibition of dihydroceramide desaturase by the sphingosine kinase inhibitors, SKi or ABC294640, induces growth arrest in androgen-independent LNCaP-AI prostate cancer cells.
    McNaughton M; Pitman M; Pitson SM; Pyne NJ; Pyne S
    Oncotarget; 2016 Mar; 7(13):16663-75. PubMed ID: 26934645
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of Uremic Toxins for Kidney, Cardiovascular, and Bone Dysfunction.
    Fujii H; Goto S; Fukagawa M
    Toxins (Basel); 2018 May; 10(5):. PubMed ID: 29772660
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Accumulation of protein-bound uremic toxins: the kidney remains the leading culprit in the gut-liver-kidney axis.
    Jourde-Chiche N; Burtey S
    Kidney Int; 2020 Jun; 97(6):1102-1104. PubMed ID: 32444090
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vascular incompetence in dialysis patients--protein-bound uremic toxins and endothelial dysfunction.
    Jourde-Chiche N; Dou L; Cerini C; Dignat-George F; Brunet P
    Semin Dial; 2011; 24(3):327-37. PubMed ID: 21682773
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Carbon Nanotube/Conducting Polymer Hybrid Nanofibers as Novel Organic Bioelectronic Interfaces for Efficient Removal of Protein-Bound Uremic Toxins.
    Yen SC; Liu ZW; Juang RS; Sahoo S; Huang CH; Chen P; Hsiao YS; Fang JT
    ACS Appl Mater Interfaces; 2019 Nov; 11(47):43843-43856. PubMed ID: 31663727
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Canagliflozin reduces plasma uremic toxins and alters the intestinal microbiota composition in a chronic kidney disease mouse model.
    Mishima E; Fukuda S; Kanemitsu Y; Saigusa D; Mukawa C; Asaji K; Matsumoto Y; Tsukamoto H; Tachikawa T; Tsukimi T; Fukuda NN; Ho HJ; Kikuchi K; Suzuki C; Nanto F; Suzuki T; Ito S; Soga T; Tomioka Y; Abe T
    Am J Physiol Renal Physiol; 2018 Oct; 315(4):F824-F833. PubMed ID: 29167170
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dietary fibre intake is low in paediatric chronic kidney disease patients but its impact on levels of gut-derived uraemic toxins remains uncertain.
    El Amouri A; Snauwaert E; Foulon A; Vande Moortel C; Van Dyck M; Van Hoeck K; Godefroid N; Glorieux G; Van Biesen W; Vande Walle J; Raes A; Eloot S
    Pediatr Nephrol; 2021 Jun; 36(6):1589-1595. PubMed ID: 33387017
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Uremia Impacts VE-Cadherin and ZO-1 Expression in Human Endothelial Cell-to-Cell Junctions.
    Maciel RAP; Cunha RS; Busato V; Franco CRC; Gregório PC; Dolenga CJR; Nakao LS; Massy ZA; Boullier A; Pecoits-Filho R; Stinghen AEM
    Toxins (Basel); 2018 Oct; 10(10):. PubMed ID: 30301260
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of Uremic Toxins from the Gut Microbiota on Bone: A Brief Look at Chronic Kidney Disease.
    Black AP; Cardozo LF; Mafra D
    Ther Apher Dial; 2015 Oct; 19(5):436-40. PubMed ID: 25944654
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of dihydroceramide desaturase activity by the sphingosine kinase inhibitor SKI II.
    Cingolani F; Casasampere M; Sanllehí P; Casas J; Bujons J; Fabrias G
    J Lipid Res; 2014 Aug; 55(8):1711-20. PubMed ID: 24875537
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting Uremic Toxins to Prevent Peripheral Vascular Complications in Chronic Kidney Disease.
    Wu CL; Tarng DC
    Toxins (Basel); 2020 Dec; 12(12):. PubMed ID: 33419312
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gamma-tocotrienol profoundly alters sphingolipids in cancer cells by inhibition of dihydroceramide desaturase and possibly activation of sphingolipid hydrolysis during prolonged treatment.
    Jang Y; Rao X; Jiang Q
    J Nutr Biochem; 2017 Aug; 46():49-56. PubMed ID: 28456081
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Impact of Uremic Toxicity Induced Inflammatory Response on the Cardiovascular Burden in Chronic Kidney Disease.
    Claro LM; Moreno-Amaral AN; Gadotti AC; Dolenga CJ; Nakao LS; Azevedo MLV; de Noronha L; Olandoski M; de Moraes TP; Stinghen AEM; Pécoits-Filho R
    Toxins (Basel); 2018 Sep; 10(10):. PubMed ID: 30249039
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of Uremic Toxins in Early Vascular Ageing and Calcification.
    Kyriakidis NC; Cobo G; Dai L; Lindholm B; Stenvinkel P
    Toxins (Basel); 2021 Jan; 13(1):. PubMed ID: 33401534
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular mechanisms underlying uremic toxin-related systemic disorders in chronic kidney disease: focused on β
    Yamamoto S
    Clin Exp Nephrol; 2019 Feb; 23(2):151-157. PubMed ID: 29869756
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Role of Gut-Derived, Protein-Bound Uremic Toxins in the Cardiovascular Complications of Acute Kidney Injury.
    Caillard P; Bennis Y; Six I; Bodeau S; Kamel S; Choukroun G; Maizel J; Titeca-Beauport D
    Toxins (Basel); 2022 May; 14(5):. PubMed ID: 35622583
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells.
    Motojima M; Hosokawa A; Yamato H; Muraki T; Yoshioka T
    Kidney Int; 2003 May; 63(5):1671-80. PubMed ID: 12675842
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oral Charcoal Adsorbents Attenuate Neointima Formation of Arteriovenous Fistulas.
    Shih YC; Wu CC; Wang SC; Liou JY; Huang PH; Tarng DC
    Toxins (Basel); 2020 Apr; 12(4):. PubMed ID: 32276394
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Continuous Reduction of Protein-Bound Uraemic Toxins with Improved Oxidative Stress by Using the Oral Charcoal Adsorbent AST-120 in Haemodialysis Patients.
    Yamamoto S; Kazama JJ; Omori K; Matsuo K; Takahashi Y; Kawamura K; Matsuto T; Watanabe H; Maruyama T; Narita I
    Sci Rep; 2015 Sep; 5():14381. PubMed ID: 26395517
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CB1 cannabinoid receptor antagonist attenuates left ventricular hypertrophy and Akt-mediated cardiac fibrosis in experimental uremia.
    Lin CY; Hsu YJ; Hsu SC; Chen Y; Lee HS; Lin SH; Huang SM; Tsai CS; Shih CC
    J Mol Cell Cardiol; 2015 Aug; 85():249-61. PubMed ID: 26093151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.